{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:pharm:antiplatelet-resistance",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:26:00.000Z",
    "updated": "2026-01-07T03:26:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.88,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "pharmacogenomics",
    "difficulty": "advanced",
    "importance": "moderate"
  },
  "content": {
    "title": "Antiplatelet Resistance",
    "description": "Laboratory and clinical resistance to antiplatelet agents",
    "key_concepts": [
      {
        "concept": "Aspirin Resistance",
        "details": "5-40% prevalence depending on definition; may reflect noncompliance, drug interactions, or true resistance"
      },
      {
        "concept": "Clopidogrel Resistance",
        "details": "CYP2C19 polymorphisms affect metabolism; poor metabolizers have reduced response"
      },
      {
        "concept": "Testing",
        "details": "Platelet function tests available (VerifyNow, vasodilator-stimulated phosphoprotein)"
      },
      {
        "concept": "Clinical Utility",
        "details": "Routine testing not recommended; consider in recurrent events despite therapy"
      }
    ],
    "clinical_significance": "May explain some treatment failures but routine testing not standard"
  },
  "provenance": {
    "primary_sources": ["Tantry US et al. Circ Cardiovasc Interv 2013"]
  }
}
